Abstract:INTRODUCTION:Hepatocellular carcinoma is currently the second leading cause of cancer-related deaths worldwide with an increasing incidence.OBJECTIVE:The objective of this study is to investigate the effect of vascular endothelial growth factor small interfering RNA (VEGF-siRNA) on rabbit VX2 carcinoma cell viability in vitro and the effect of transarterial embolization (TAE)-mediated VEGF-siRNA delivery on the growth of rabbit VX2 liver-transplanted model in vivo.METHODS:Quantitative reverse transcription polymerase chain reaction, enzyme-linked immunosorbent assay, and Western blot technologies were used to detect the expression level of VEGF. TAE and computed tomography scan were used to deliver the VEGF-siRNA and detect the tumor volume in vivo, respectively. Microvessel density was detected by immunohistochemistry with CD34 antibody. A biochemical autoanalyzer was used to evaluate the hepatic and renal toxicity.RESULTS:The designed VEGF-siRNAs could effectively decrease the expression levels of VEGF mRNA and protein in vitro and in vivo. In vitro, the viability of rabbit VX2 carcinoma cells was reduced by 38.5%±7.3% (VEGF-siRNA no 1) and 30.0%±5.8% (VEGF-siRNA no 3) at 48 hours after transfection. Moreover, in rabbit VX2 liver-transplanted model, the growth ratios of tumors at 28 days after TAE-mediated siRNA delivery were 155.18%±19.42% in the control group, 79.67%±19.63% in the low-dose group, and 36.09%±15.73% in the high-dose group, with significant differences among these three groups. Microvessel density dropped to 34.22±4.01 and 22.63±4.07 in the low-dose group and high-dose group, respectively, compared with the control group (57.88±5.67), with significant differences among these three groups. Furthermore, inoculation of VX2 tumor into the liver itself at later stage induced significant increase in alanine aminotransferase and aspartate aminotransferase, indicating an obvious damage of liver functions, while treatment of VX2 tumor via TAE-mediated VEGF-siRNA had no toxicity to the livers and kidneys of rabbits, and VEGF-siRNA had the ability to protect liver damage induced by tumor growth.CONCLUSION:This is the first study to demonstrate that targeting VEGF via TAE-mediated siRNA delivery may become a powerful new option for effective treatment of hepatocellular carcinoma in the clinic.

Vastatin, an Endogenous Antiangiogenesis Polypeptide That Is Lost in Hepatocellular Carcinoma, Effectively Inhibits Tumor Metastasis

Vastatin is an Endogenous Antiangiogenesis Polypeptide Lost in Hepatocellular Carcinoma and Effectively Inhibits Tumor Metastasis

Enhanced expression of Vastatin inhibits angiogenesis and prolongs survival in murine orthotopic glioblastoma model

Inhibition of Human Hepatocellular Carcinoma Tumor Angiogenesis by Sirna Silencing of VEGF Via Hepatic Artery Perfusion.

Plasmid-encoding Vasostatin Inhibited the Growth and Metastasis of Human Hepatocellular Carcinoma Cells

A Small Interfering RNA Targeting Vascular Endothelial Growth Factor Efficiently Inhibits Growth of VX2 Cells and VX2 Tumor Model of Hepatocellular Carcinoma in Rabbit by Transarterial Embolization-Mediated Sirna Delivery.

Recombinant canstatin inhibits the progression of hepatocellular carcinoma by repressing the HIF-1α/VEGF signaling pathway

Synergistic suppression effect on tumor growth of hepatocellular carcinoma by combining oncolytic adenovirus carrying XAF1 with cisplatin

Suppression Of Angiogenesis And Tumor Growth In Vitro And In Vivo Using An Anti-Angiopoietin-2 Single-Chain Antibody

Abstract 4177: Inhibition of Tumor Malignancy by Anti-Angiogenic Therapies in Orthotopic Mouse Models of Hepatocellular Carcinoma

Vasorin is a potential serum biomarker and drug target of hepatocarcinoma screened by subtractive-EMSA-SELEX to clinic patient serum.

Atorvastatin shows antitumor effect in hepatocellular carcinoma development by inhibiting angiogenesis via TGF-β1/pERK signaling pathway

293. Sustained Expression of Kringle 1 Domain of Human Hepatocyte Growth Factor (HGFK1) Effectively Inhibits Angiogenesis, Growth and Metastasis of Hepatocellular Carcinoma

Inhibitory Effect of Humanized Anti-Vegfr-2 ScFv-As2O3-stealth Nanoparticles Conjugate on Growth of Human Hepatocellular Carcinoma: in Vitro and in Vivo Studies

Long-Term Expression of Angiostatin Suppresses Metastatic Liver Cancer in Mice

A Novel Peptide from Abalone (Haliotis discus hannai) to Suppress Metastasis and Vasculogenic Mimicry of Tumor Cells and Enhance Anti-Tumor Effect In Vitro

Tumor Suppressor XAF1 Induces Apoptosis, Inhibits Angiogenesis and Inhibits Tumor Growth in Hepatocellular Carcinoma

Inhibitory Efficacy of Local Angiostatin Expression in Treatment of Human Hepatic Carcinoma Cells

HGFK1 Enhances the Anti-Tumor Effects of Angiogenesis Inhibitors via Inhibition of CD90+ CSCs in Hepatocellular Carcinoma

Low-Molecular Weight Chitosan/Vascular Endothelial Growth Factor Short Hairpin Rna for the Treatment of Hepatocellular Carcinoma

A Novel Liver Cancer-Selective Histone Deacetylase Inhibitor Is Effective Against Hepatocellular Carcinoma and Induces Durable Responses with Immunotherapy